BENZENO SHARON
SEC CIK 1780854 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ADPT | Adaptive Biotechnologies Corp | Chief Commercial Ofc Imm Med | 376.0K | — | $15.24M | 16 | 2022-03-04 | 2026-06-26 |
Most active insiders at ADPT, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | ROBINS CHAD M | CEO, COB, Dir | — | $39.80M |
| 2 | ROBINS HARLAN S | CSO | — | $29.65M |
| 3 | BENZENO SHARON | Chief Commercial Ofc Imm Med | — | $14.69M |
| 4 | RUBINSTEIN JULIE | Pres, COO | — | $13.37M |
| 5 | LO FRANCIS | CHRO | — | $13.21M |
| 6 | PISKEL KYLE | CFO | — | $3.58M |
| 7 | NEUPERT PETER M | Dir | — | $3.14M |
| 8 | GRIFFIN MICHELLE RENEE | Dir | — | $2.00M |
| 9 | BOBULSKY SUSAN | Chief Commercial Off, MRD | — | $1.20M |
| 10 | HERSHBERG ROBERT | Dir | — | $1.12M |
Transactions 16
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-06-30 19:25 | 2026-06-26+ | ADPT | Adaptive Biotechnologies Corp | BENZENO SHARON | Chief Commercial Ofc Imm Med | M - OptEx | $7.75 | +114.3K | 376.0K | +44% | +$885.6K |
| DMT | 2026-06-30 19:25 | 2026-06-26+ | ADPT | Adaptive Biotechnologies Corp | BENZENO SHARON | Chief Commercial Ofc Imm Med | S - Sale+OE | $21.13 | -165.8K | 221.3K | -43% | -$3.50M |
| 2026-03-13 | 2026-03-11 | ADPT | Adaptive Biotechnologies Corp | BENZENO SHARON | Chief Commercial Ofc Imm Med | S - Sale | $13.17 | -63.1K | 272.8K | -19% | -$831.1K | |
| 2026-03-06 | 2026-03-04 | ADPT | Adaptive Biotechnologies Corp | BENZENO SHARON | Chief Commercial Ofc Imm Med | A - Grant | $0.00 | +39.1K | 335.9K | +13% | $0 | |
| DM | 2025-12-08 | 2025-12-04 | ADPT | Adaptive Biotechnologies Corp | BENZENO SHARON | Chief Commercial Ofc Imm Med | M - OptEx | $8.24 | +12.6K | 305.2K | +4% | +$103.8K |
| D | 2025-12-08 | 2025-12-04 | ADPT | Adaptive Biotechnologies Corp | BENZENO SHARON | Chief Commercial Ofc Imm Med | S - Sale+OE | $16.85 | -12.6K | 296.8K | -4% | -$212.4K |
| DM | 2025-11-24 | 2025-11-20+ | ADPT | Adaptive Biotechnologies Corp | BENZENO SHARON | Chief Commercial Ofc Imm Med | M - OptEx | $8.75 | +510.5K | 594.7K | +606% | +$4.46M |
| DM | 2025-11-24 | 2025-11-20+ | ADPT | Adaptive Biotechnologies Corp | BENZENO SHARON | Chief Commercial Ofc Imm Med | S - Sale+OE | $16.73 | -606.4K | 296.8K | -67% | -$10.14M |
| D | 2025-03-06 | 2025-03-04 | ADPT | Adaptive Biotechnologies Corp | BENZENO SHARON | Chief Commercial Ofc Imm Med | A - Grant | $0.00 | +110.0K | 437.4K | +34% | $0 |
| DM | 2025-03-06 | 2025-03-05 | ADPT | Adaptive Biotechnologies Corp | BENZENO SHARON | Chief Commercial Ofc Imm Med | S - Sale | $6.98 | -44.7K | 392.7K | -10% | -$311.8K |
| DM | 2024-03-06 | 2024-03-05 | ADPT | Adaptive Biotechnologies Corp | BENZENO SHARON | Chief Commercial Ofc Imm Med | S - Sale | $3.44 | -29.4K | 346.1K | -8% | -$101.0K |
| D | 2024-03-06 | 2024-03-04 | ADPT | Adaptive Biotechnologies Corp | BENZENO SHARON | Chief Commercial Ofc Imm Med | A - Grant | $0.00 | +133.0K | 356.8K | +59% | $0 |
| D | 2023-03-08 | 2023-03-06 | ADPT | Adaptive Biotechnologies Corp | BENZENO SHARON | Chief Commercial Ofc Imm Med | S - Sale | $8.57 | -11.7K | 223.8K | -5% | -$100.7K |
| D | 2023-03-08 | 2023-03-06 | ADPT | Adaptive Biotechnologies Corp | BENZENO SHARON | Chief Commercial Ofc Imm Med | A - Grant | $0.00 | +133.0K | 235.6K | +130% | $0 |
| D | 2022-03-08 | 2022-03-07 | ADPT | Adaptive Biotechnologies Corp | BENZENO SHARON | Chief Business Development Off | S - Sale | $12.01 | -2,670 | 102.6K | -3% | -$32.1K |
| D | 2022-03-08 | 2022-03-04 | ADPT | Adaptive Biotechnologies Corp | BENZENO SHARON | Chief Business Development Off | A - Grant | $0.00 | +82.4K | 105.3K | +360% | $0 |
Purchase Sale Sale after option exercise All abbreviations